Bezuclastinib/Sunitinib Combination Under Evaluation in Advanced GIST

The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.

Related Keywords

London ,City Of ,United Kingdom ,Houston ,Texas ,United States ,Robin Jones ,Neeta Somaiah ,Department Of Sarcoma Medical Oncology ,University Of Texas Md Anderson Cancer Center ,Division Of Cancer Medicine ,Sarcoma Unit ,Royal Marsden ,Sarcoma Medical Oncology ,Cancer Medicine ,Cancer Center ,Bezuclastinib ,Sunitinib ,Gastrointestinal Stromal Tumor ,Peak Trial ,Nct05208047 ,